Medpace Holdings is a holding company. Through its subsidiaries, the company is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company provides a range of services supporting the clinical development process from Phase I to Phase IV. The company provides these services across a range of therapeutic areas. The company's line of clinical development services includes, but is not limited to, study start-up, patient recruitment and retention, clinical monitoring, risk-based monitoring, medical writing, data management, pharmacovigilance, and molecular and genetic testing.

Tela Bio is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which the company refers to as a reinforced tissue matrix. The company serves customers in the United States.

Tricida is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract.